Strategies for Prevention and Screening of CRM Conditions

Key Takeaways

Integrating early intervention strategies for HF and T2D can prevent CKD, enhancing patient outcomes and reducing disease progression.
Standardized protocols and education are crucial for improving early CKD screening across diverse healthcare settings.
Value-based care models and technology can incentivize healthcare providers to prioritize early screening and intervention for CRM conditions.
Reimbursement models that reward early detection and management can encourage proactive healthcare practices, reducing long-term costs.

Experts in cardiometabolic risk management explore strategies for the prevention and screening of cardiometabolic conditions.

EP: 1.The Impact of CRM Diseases in the US: Burden, Prevalence, and Obesity

Now Viewing

EP: 2.Strategies for Prevention and Screening of CRM Conditions

EP: 3.The Link Between Obesity and CRM Conditions

EP: 4.Challenges in Managing Co-Morbid CRM Conditions

EP: 5.Contemporary Guidelines for CRM Conditions

EP: 6.Reasons for Low Adherence to Guidelines for CRM Conditions

EP: 7.Overcoming Barriers to Prescribing First-Line Medications for CRM Conditions

EP: 8.Educational Initiatives to Enhance Guideline Adherence in CRM

EP: 9.Addressing Gaps in CKD, T2D, and CVD Guidelines

EP: 10.Care Coordination for High-Risk CRM Patients

EP: 11.Takeaways from the UH CINEMA Program

EP: 12.Exploring the Kidney-CHAMP Study

EP: 13.Insights from the COORDINATE-Diabetes Trial

EP: 14.Coordinating Initiatives to Enhance CRM Care

EP: 15.Implementing CRM Learnings and Utilization of Telehealth

Video content above is prompted by the following:

What does a successful CRM prevention or screening program look like in practice?
Can early intervention in patients with HF or T2D prevent CKD or vice versa?
How can early screening for CKD be improved and effectively implemented across different healthcare settings?
What specific steps can healthcare providers take to incentivize early screening and intervention for CRM conditions?
How can payers structure their reimbursement models to incentivize early detection and management of conditions like CKD, HF, and T2D?

This activity is supported by Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Company who provided financial support for this program.